Neuraxis (NRXS) Other financing activities (2024 - 2025)
Neuraxis (NRXS) posted Other financing activities of $95201.0 for Q4 2025, up 328179.31% sequentially from $29.0 in Q2 2025, and down 43.44% YoY from $168322.0 in Q4 2024.
Neuraxis (NRXS) Other financing activities (2024 - 2025) Analysis & Trends
Neuraxis has reported Other financing activities for 2 years, with the latest figure at $95201.0 in Q4 2025.
- Quarterly Other financing activities fell 43.44% year-over-year to $95201.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $376016.0 (up 93.32% YoY) and the FY2025 annual result came in at $1.1 million, up 464.62% from the prior year.
- Other financing activities rose to $95201.0 in Q4 2025 per NRXS's latest filing, from $29.0 in the prior quarter.
- Over five years, Other financing activities peaked at $200250.0 in Q1 2024 and troughed at -$174070.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 95,201.00 |
| Dec 31, 2025 | 95,201.00 |
| Jun 30, 2025 | 29.00 |
| Jun 30, 2025 | 29.00 |
| Mar 31, 2025 | 112,493.00 |
| Mar 31, 2025 | 112,493.00 |
| Dec 31, 2024 | 168,322.00 |
| Dec 31, 2024 | 168,322.00 |
| Jun 30, 2024 | -174,070.00 |
| Jun 30, 2024 | -174,070.00 |
| Mar 31, 2024 | 200,250.00 |
| Mar 31, 2024 | 200,250.00 |